

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number  
**WO 01/98302 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 487/04**,  
A61K 31/519, A61P 35/00 // (C07D 487/04, 257:00,  
239:00)

1125 Trenton-Harbourton Road, Titusville, CA 08560  
(US).

(21) International Application Number: PCT/EP01/06747

(74) Agent: **DE CORTE, Filip**; Janssen Pharmaceutica N.V.,  
Turnhoutseweg 30, B-2340 Beerse (BE).

(22) International Filing Date: 13 June 2001 (13.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
00202181.4 22 June 2000 (22.06.2000) EP

(71) Applicant (for all designated States except US):  
**JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Patent  
Department, Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **VENET, Marc**,  
**Gaston** [FR/FR]; Janssen-Cilag S.A., 1, rue Camille  
Desmoulins, TSA 91003, F-92787 Cedex 9 Issy-les  
Moulineaux (FR). **ANGIBAUD, Patrick, René** [FR/FR];  
Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA  
91003, F-92787 Cedex 9 Issy-les Moulineaux (FR). **END**,  
**David, William** [US/US]; Janssen Pharmaceutica Inc.,

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER

(57) Abstract: The invention relates to (-)-5-(3-Chlorophenyl)- $\alpha$ -(4-chlorophenyl)- $\alpha$ -(1-methyl-1H-imidazol-5-yl)tetrazolo-[1,5-a]quinazoline-7-methanamine and its pharmaceutically acceptable acid addition salts, and the use of such compounds in medicine especially for the treatment of cancer.



WO 01/98302 A1

## FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER

---

- 5 The present invention is concerned with a novel 1,2-annelated quinazoline enantiomer, the preparation thereof, pharmaceutical compositions comprising said novel compound and the use of this compound as a medicine as well as methods of treatment by administering said compound.
- 10 Oncogenes frequently encode protein components of signal transduction pathways which lead to stimulation of cell growth and mitogenesis. Oncogene expression in cultured cells leads to cellular transformation, characterized by the ability of cells to grow in soft agar and the growth of cells as dense foci lacking the contact inhibition exhibited by non-transformed cells. Mutation and/or overexpression of certain
- 15 oncogenes is frequently associated with human cancer. A particular group of oncogenes is known as *ras* which have been identified in mammals, birds, insects, mollusks, plants, fungi and yeasts. The family of mammalian *ras* oncogenes consists of three major members ("isoforms") : H-*ras*, K-*ras* and N-*ras* oncogenes. These *ras* oncogenes code for highly related proteins generically known as p21<sup>*ras*</sup>. Once
- 20 attached to plasma membranes, the mutant or oncogenic forms of p21<sup>*ras*</sup> will provide a signal for the transformation and uncontrolled growth of malignant tumor cells. To acquire this transforming potential, the precursor of the p21<sup>*ras*</sup> oncoprotein must undergo an enzymatically catalyzed farnesylation of the cysteine residue located in a carboxyl-terminal tetrapeptide. Therefore, inhibitors of the enzymes that catalyzes this
- 25 modification, i.e. farnesyl transferase, will prevent the membrane attachment of p21<sup>*ras*</sup> and block the aberrant growth of *ras*-transformed tumors. Hence, it is generally accepted in the art that farnesyl protein transferase inhibitors can be very useful as anticancer agents for tumors in which *ras* contributes to transformation.
- 30 Since mutated oncogenic forms of *ras* are frequently found in many human cancers, most notably in more than 50 % of colon and pancreatic carcinomas (Kohl et al., *Science*, vol 260, 1834 - 1837, 1993), it has been suggested that farnesyl protein transferase inhibitors can be very useful against these types of cancer.
- 35 In WO 97/16443, WO 97/21701, WO 98/40383 and WO 98/49157, there are described 2-quinolone derivatives which exhibit farnesyl transferase inhibiting activity. Other quinolone compounds having farnesyl transferase inhibiting activity are described in

- WO 00/12498, 00/12499 and 00/47574. WO 00/39082 describes a class of novel 1,2-annulated quinoline and quinazoline compounds, bearing a nitrogen- or carbon-linked imidazole, which show farnesyl protein transferase inhibiting activity. Among such compounds described in the latter patent, specification is ( $\pm$ )-5-(3-chlorophenyl)- $\alpha$ -(4-chlorophenyl)- $\alpha$ -(1-methyl-1*H*-imidazol-5-yl)tetrazolo[1,5-*a*]quinazoline-7-methanamine which was obtained in the form of an enantiomeric mixture. We have now separated the mixture and have found that the (-) enantiomer has especially advantageous pharmacological properties compared with the enantiomeric mixture
- 10 The present invention thus concerns (-)-5-(3-chlorophenyl)- $\alpha$ -(4-chlorophenyl)- $\alpha$ -(1-methyl-1*H*-imidazol-5-yl)tetrazolo[1,5-*a*]quinazoline-7-methanamine and its pharmaceutically acceptable acid addition salts.

- 15 The above (-) enantiomer is hereinafter referred to as the compound according to the invention.

- The compound of the invention is generally present in a substantially pure form, i.e. substantially free of the opposite (+) enantiomer, for example containing less than 5 % w/w, preferably less than 2 % w/w, and advantageously less than 1 % w/w of the latter enantiomer.
- 20

- The pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compound of the invention is able to form. The latter compound can be converted into its pharmaceutically acceptable acid addition salts by treating said base form with an appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (*i.e.* butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-amino-salicylic, pamoic and the like acids.
- 25
- 30

- The term acid addition salts also comprises the hydrates and the solvent addition forms which the compound of the invention is able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
- 35

Whenever used hereinafter, the term "compound of the invention" is meant to include also the pharmaceutically acceptable acid addition salts.

5 The (-) enantiomer according to the present invention may be prepared by separation of the parent enantiomeric mixture described in the above WO 00/39082. The separation may be effected in conventional manner for example by reaction with a suitable chiral acid such as (+)-6-aminopenicillanic acid, D or L aspartic acid, (1S,3R) or (1R,3S)-camphoric acid, (1S) or (1R) -10-camphorsulfonic acid, carbobenzyloxy-L-proline, cholic acid, dehydrocholic acid, deoxycholic acid, (2S,3S) or (2R,3R) dibenzoyltartaric acid, (2S,3S) or (2R,3R) diacetyltartaric acid, (2S,3S) or (2R,3R)-tartaric acid, (2S,3S) or (2R,3R) ditoluoyltartaric acid; 2,3:4,6-di-O-isopropylidene-2-keto-L-gulonic acid, (+)-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid, (R) or (S)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane-2-oxide, D-gluconic acid, D or L-glutamic acid, D-isoascorbic acid, (S) or (R)-2-hydroxypropanoic acid, lactobionic acid, D or L-malic acid, (R) or (S)-mandelic acid, L-2-((4-methoxyphenyl)sulfonyl)-amino pentanedioic acid, L-2-((4-methylphenyl)sulfonyl)amino pentanedioic acid, (S)-6-methoxy- $\alpha$ -methyl-2-naphtalene acetic acid, (S)-2-(phenylcarbamoyloxy)-propanoic acid, (-)-3-pinane carboxylic acid, (R) or (S)-2-pyrrolidone-5-carboxylic acid or (R)-thiazolidine-4-carboxylic acid. The resulting salt forms are subsequently separated, for example, by selective or fractional crystallization and the desired enantiomer is liberated therefrom by alkali.

An alternative manner of separating the desired enantiomeric form from the parent mixture involves liquid chromatography using a chiral stationary phase. The pure enantiomeric form may also be derived from the corresponding pure enantiomeric form of the appropriate starting materials, provided that the reaction occurs stereospecifically. The pure enantiomeric form may also be obtained starting from an appropriate racemic starting material provided that the reaction occurs enantiospecifically. The pure enantiomeric form can be prepared by reacting the parent enantiomeric mixture with one enantiomer of some chiral agents such as acids or acid chlorides to obtain diastereoisomeric mixtures, separating it, for example by selective or fractional crystallization or by using liquid chromatography, into pure diastereoisomers. The appropriate diastereoisomer can then be cleaved into the desired enantiomer. The parent enantiomeric mixture may be prepared in accordance with the processes described in the above WO 00/39082 or as described more specifically herein.

The compound of the invention and its pharmaceutically acceptable acid addition salts have valuable pharmacological properties in that they have a farnesyl protein transferase (FPTase) inhibitory effect which is surprisingly potent in comparison with  
5 that of the parent enantiomeric mixture. Thus, the latter mixture has a IC<sub>50</sub> FPTase inhibitory activity of 1.1 nM whereas the (-) enantiomer has a corresponding activity of 0.7 nM.

This invention provides a method for inhibiting the abnormal growth of cells, including  
10 transformed cells, by administering an effective amount of the compound of the invention. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g. loss of contact inhibition). This includes the abnormal growth of : (1) tumor cells (tumors) expressing an activated *ras* oncogene; (2) tumor  
15 cells in which the *ras* protein is activated as a result of oncogenic mutation of another gene; (3) benign and malignant cells of other proliferative diseases in which aberrant *ras* activation occurs. Furthermore, it has been suggested in literature that *ras* oncogenes not only contribute to the growth of tumors *in vivo* by a direct effect on tumor cell growth but also indirectly, *i.e.* by facilitating tumor-induced angiogenesis (Rak. J. et al, *Cancer Research*, 55, 4575-4580, 1995). Hence, pharmacologically  
20 targeting mutant *ras* oncogenes could conceivably suppress solid tumor growth *in vivo*, in part, by inhibiting tumor-induced angiogenesis.

This invention also provides a method for inhibiting tumor growth by administering an effective amount of the compound of the invention to a subject, e.g. a mammal (and  
25 more particularly a human) in need of such treatment. In particular, this invention provides a method for inhibiting the growth of tumors expressing an activated *ras* oncogene by the administration of an effective amount of the compound of the invention. Examples of tumors which may be inhibited, but are not limited to, lung cancer (e.g. adenocarcinoma and including non-small cell lung cancer), pancreatic  
30 cancers (e.g. pancreatic carcinoma such as, for example exocrine pancreatic carcinoma), colon cancers (e.g. colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), hematopoietic tumors of lymphoid lineage (e.g. acute lymphocytic leukemia, B-cell lymphoma, Burkitt's lymphoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular  
35 cancer, myelodysplastic syndrome (MDS), tumors of mesenchymal origin (e.g. fibrosarcomas and rhabdomyosarcomas), melanomas, teratocarcinomas,

neuroblastomas, gliomas, benign tumor of the skin (e.g. keratoacanthomas), breast carcinoma (e.g. advanced breast cancer), kidney carcinoma, ovary carcinoma, bladder carcinoma and epidermal carcinoma.

- 5 This invention may also provide a method for inhibiting proliferative diseases, both benign and malignant, wherein *ras* proteins are aberrantly activated as a result of oncogenic mutation in genes. With said inhibition being accomplished by the administration of an effective amount of the compound described herein, to a subject in need of such a treatment. For example, the benign proliferative disorder neuro-  
10 fibromatosis, or tumors in which *ras* is activated due to mutation or overexpression of tyrosine kinase oncogenes, may be inhibited by the compounds of this invention.

The compound according to the invention can be used for other therapeutic purposes, for example:

- 15 a) the sensitisation of tumors to radiotherapy by administering the compound according to the invention before, during or after irradiation of the tumor for treating cancer, for example as described in WO 00/01411;  
b) treating athropathies such as rheumatoid arthritis, osteoarthritis, juvenile arthritis, gout, polyarthritis, psoriatic arthritis, ankylosing spondylitis and  
20 systemic lupus erythematosus, for example as described in WO 00/01386;  
c) inhibiting smooth muscle cell proliferation including vascular proliferative disorders, atherosclerosis and restenosis, for example as described in WO 98/55124;  
d) treating inflammatory conditions such as ulcerative colitis, Crohn's disease,  
25 allergic rhinitis, graft vs host disease, conjunctivitis, asthma, ARDS, Behcets disease, transplant rejection, uticaria, allergic dermatitis, alopecia areata, scleroderma, exanthem, eczema, dermatomyositis, acne, diabetes, systemic lupus erythematosus, Kawasaki's disease, multiple sclerosis, emphysema, cystic fibrosis and chronic bronchitis;  
e) treating endometriosis, uterine fibroids, dysfunctional uterine bleeding and endometrial hyperplasia;  
f) treating ocular vascularisation including vasculopathy affecting retinal and choroidal vessels;  
g) treating pathologies resulting from heterotrimeric G protein membrane fixation  
35 including diseases related to following biological functions or disorders; smell, taste, light, perception, neurotransmission, neurodegeneration, endocrine and

- exocrine gland functioning, autocrine and paracrine regulation, blood pressure, embryogenesis, viral infections, immunological functions, diabetes, obesity;
- h) inhibiting viral morphogenesis for example by inhibiting the prenylation or the post-prenylation reactions of a viral protein such as the large delta antigen of hepatitis D virus; and the treatment of HIV infections;
- 5 i) treating polycystic kidney disease;
- j) suppressing induction of inducible nitric oxide including nitric oxide or cytokine mediated disorders, septic shock, inhibiting apoptosis and inhibiting nitric oxide cytotoxicity;
- 10 k) treating malaria.

Hence, the present invention discloses the compound of the invention for use as a medicine as well as the use of this compound for the manufacture of a medicament for treating one or more of the above mentioned conditions.

15

For the treatment of the above conditions, the compound of the invention may be advantageously employed in combination with one or more other anti-cancer agents for example selected from platinum coordination compounds for example cisplatin or carboplatin, taxane compounds for example paclitaxel or docetaxel, camptothecin compounds for example irinotecan or topotecan, anti-tumor vinca alkaloids for example vinblastine, vincristine or vinorelbine, anti-tumor nucleoside derivatives for example 5-fluorouracil, gemcitabine or capecitabine, nitrogen mustard or nitrosourea alkylating agents for example cyclophosphamide, chlorambucil, carmustine or lomustine, anti-tumor anthracycline derivatives for example daunorubicin, doxorubicin or idarubicin; HER2 antibodies for example trastuzumab; and anti-tumor podophyllotoxin derivatives for example etoposide or teniposide; and antiestrogen agents including estrogen receptor antagonists or selective estrogen receptor modulators preferably tamoxifen, or alternatively toremifene, droloxifene, faslodex and raloxifene, or aromatase inhibitors such as exemestane, anastrozole, letrozole and vorozole.

20

25

30

In view of its useful pharmacological properties, the subject compound may be formulated into various pharmaceutical forms for administration purposes.

35 To prepare the pharmaceutical compositions of this invention, an effective amount of the compound, in base or acid addition salt form, as the active ingredient is combined

in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, to aid solubility for example, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.



Those skilled in the art could easily determine the effective amount from the test results presented above. In general it is contemplated that an effective amount would be from 0.01 mg/kg to 100 mg/kg body weight, and in particular from 0.05 mg/kg to 10 mg/kg body weight. For an adult it is generally preferred to administer a daily dose of 10 to 600mg, advantageously 50 to 500mg and especially 100 to 400 mg of active ingredient, doses of 200 or 300mg being particularly preferred. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 10 to 500 mg, and in particular 50 mg to 300 mg of active ingredient per unit dosage form; dosage units containing 50mg, 100mg, 200mg or 300mg of active ingredient are especially preferred.


The following examples are provided for purposes of illustration.

#### 15 Experimental part

Hereinafter "THF" means tetrahydrofuran, "DIPE" means diisopropylether and "EtOAc" means ethyl acetate.

#### Example


a) Preparation of




intermediate (2)

20 A mixture of 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-2(1H)-quinazolinone (intermediate 1) (0.0506 mol), prepared as described in WO98/49157, in POCl<sub>3</sub> (100ml) was stirred and refluxed 1 hour. The solvent was evaporated to dryness. The residue was taken up several times in CH<sub>2</sub>Cl<sub>2</sub>. The solvent was evaporated till dryness. The residue was taken up in CH<sub>2</sub>Cl<sub>2</sub>. The mixture was poured out into ice/NH<sub>4</sub>OH. The organic layer was separated, dried (MgSO<sub>4</sub>), filtered, and the solvent was evaporated till dryness. The residue (24.2g) was crystallized from CH<sub>3</sub>CN. The precipitate was filtered off and dried, yielding: 19.8g of intermediate (2) (94%), mp. 152°C.

## b) Preparation of



A solution of n-butyllithium in hexane (1.6 M) (90ml) was added dropwise at -70°C under N<sub>2</sub> flow to a mixture of 1-methylimidazole (0.144mol) in THF (120ml). The mixture was stirred at -70°C for 15 minutes. Chlorotriethylsilane (0.148mol) was added dropwise at -70°C and the mixture stirred 15 min. at this temperature. A solution of n-butyllithium in hexane (1.6 M) (80ml) was added dropwise. The mixture was stirred at -70°C for 15 min. A mixture of intermediate (2) (0.0822mol) in THF (300ml) was added dropwise. The mixture was stirred at -70°C for 1 hour, hydrolysed, extracted with EtOAc and decanted. The organic layer was dried (MgSO<sub>4</sub>), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel. The pure fractions were collected and the solvent was evaporated, yielding 24.9g (61%) of intermediate (3).



intermediate 2

intermediate 3

c) A mixture of intermediate (3) (0.0061 mol) and sodium azide (0.0079 mol) in N,N-dimethylacetamide (DMA) (20 ml) was stirred at 50°C for 18 hours. The mixture was cooled to room temperature and poured out into ice water. The precipitate was filtered off, washed with H<sub>2</sub>O thoroughly and taken up in CH<sub>2</sub>Cl<sub>2</sub>. The organic solution was dried, filtered and the solvent was evaporated. The residue was crystallized from CH<sub>3</sub>CN DIPE. The precipitate was filtered off and dried yielding 2.3g (75%) of (±)-5-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanol (intermediate 4); mp. 232-233°C.

- d) A mixture of intermediate (4) (0.0573mmol) and sulfonylurea (300g) was stirred at 160°C for 5 hours and then cooled. Ice water was added, then methylene chloride and the mixture was filtered over celite. The organic layer was separated, dried (MgSO<sub>4</sub>), filtered and the solvent was evaporated till dryness. The residue was purified by column chromatography over silica gel. The pure fraction were collected and the solvent was evaporated yielding 7.5g (26%) of (±)-5-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine (intermediate 5).
- e) Intermediate (5) was separated into its enantiomers and purified by column chromatography over Chiralpak AD<sup>®</sup> (eluent: hexane/EtOH 50/50; 15-35μm). The pure first (A) fractions were collected and the solvent was evaporated yielding 3.3g of residue which was crystallized from CH<sub>3</sub>CN/DIPE. The precipitate was filtered off and dried, yielding 2.55g of (-)-5-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine (compound 1)  $[\alpha]_D^{20} = -7.16^\circ$  (c=5 mg/ml MeOH); mp.=178-180°C; <sup>1</sup>H-NMR (DMSO, 400MHz) δ in ppm: 8.73(d, J=8.6Hz, 1H), 8.38(dd, J=8.6Hz, J=1.5Hz, 1H); 7.74-7.67(m, 3H); 7.64(s, 1H); 7.62-7.56(m, 2H); 7.40(d, J=8.6Hz, 2H); 7.21(d, J=8.6Hz, 2H); 5.93(s, 1H), 3.43(s, 3H); 3.40(s, broad, 2H); MS (electrospray, mode pos. OR=50V) m/z: 501-505 (M+H)<sup>+</sup>; 473-477, 391-395, 83; Anal. (C<sub>25</sub>H<sub>18</sub>Cl<sub>2</sub>N<sub>8</sub>) C calcd. 59.89 found 59.71, H calcd. 3.62 found 3.52, N calcd. 22.35 found 22.17. This compound contains less than 0.5% w/w of the (+) enantiomer as measured by HPLC (Chiralpak AD<sup>®</sup> 10μm eluent Hexane/Ethanol 50/50).

The second (B) fractions were collected and evaporated yielding 3.3g of residue which was crystallized from CH<sub>3</sub>CN/DIPE. The precipitate was filtered off and dried yielding 2.6g of (+)-5-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine (compound 2)  $[\alpha]_D^{20} = +5.9^\circ$  (c=5 mg/ml MeOH). This compound contains 4% w/w of the (-) enantiomer as measured by HPLC (Chiralpak AD<sup>®</sup> 10μm eluent Hexane/Ethanol 50/50).

### C. Pharmacological example.

#### Example C.1 : "In Vitro Assay for Inhibition of Farnesyl Protein Transferase" :

An in vitro assay for inhibition of farnesyl protein transferase was performed essentially as described in WO 98/40383, pages 33-34.

Example C.2 : "Ras-Transformed Cell Phenotype Reversion Assay".

The *ras*-transformed cell phenotype reversion assay was performed essentially as described in WO 98/40383 , pages 34-36.

Example C.3 : "Farnesyl Protein Transferase Inhibitor Secondary Tumor Model".

- 5 The farnesyl protein transferase inhibitor secondary tumor model was used as described in WO 98/40383 , page 37.

D. Composition example : Film-coated tablets

Preparation of tablet core

- 10 A mixture of 100 g of the compound of the invention, 570 g lactose and 200 g starch is mixed well and thereafter humidified with a solution of 5 g sodium dodecyl sulfate and 10 g polyvinyl-pyrrolidone in about 200 ml of water. The wet powder mixture is sieved, dried and sieved again. Then there are added 100 g microcrystalline cellulose and 15 g hydrogenated vegetable oil. The whole is mixed well and compressed into  
15 tablets, giving 10.000 tablets, each comprising 10 mg of a compound of formula (I).

Coating

- To a solution of 10 g methyl cellulose in 75 ml of denaturated ethanol there is added a solution of 5 g of ethyl cellulose in 150 ml of dichloromethane. Then there are added 75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol. 10 g of polyethylene glycol is  
20 molten and dissolved in 75 ml of dichloromethane. The latter solution is added to the former and then there are added 2.5 g of magnesium octadecanoate, 5 g of polyvinyl-pyrrolidone and 30 ml of concentrated colour suspension and the whole is homogenated. The tablet cores are coated with the thus obtained mixture in a coating apparatus.

Claims

1. (-)-5-(3-Chlorophenyl)- $\alpha$ -(4-chlorophenyl)- $\alpha$ -(1-methyl-1*H*-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine and its pharmaceutically acceptable  
5 acid addition salts.
2. (-)-5-(3-Chlorophenyl)- $\alpha$ -(4-chlorophenyl)- $\alpha$ -(1-methyl-1*H*-imidazol-5-yl)-  
tetrazolo[1,5-a]quinazoline-7-methanamine.
- 10 3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier,  
and as active ingredient a therapeutically effective amount of a compound as  
claimed in claim 1.
4. A pharmaceutical composition as claimed in claim 3 in which the active  
15 ingredient is the compound as claimed in claim 2.
5. A pharmaceutical composition as claimed in claim 3 or claim 4 in a dosage unit  
form.
- 20 6. A pharmaceutical composition as claimed in claim 5 containing 50 to 300mg of  
active ingredient in each unit dosage form.
7. A pharmaceutical composition as claimed in claim 5 or claim 6 in the form of a  
tablet.
- 25 8. A process for preparing a pharmaceutical composition as claimed in any of claims  
3 to 7 wherein a therapeutically effective amount of the active ingredient is  
intimately mixed with a pharmaceutically acceptable carrier.
- 30 9. A compound as claimed in claim 1 or claim 2 for use in medicine.
10. Use of a compound as claimed in claim 1 or claim 2 in the manufacture of a  
medicament for inhibiting tumor growth.
- 35 11. A method for inhibiting tumor growth in a subject which comprises administering  
an effective amount of compound as claimed in claim 1 or claim 2 to the subject.

12. A method as claimed in claim 11 in which the compound is administered in a daily dose of 10 to 600mg.
- 5 13. A method as claimed in claim 12 in which the compound is administered in a daily dose of 50 to 500mg.
- 10 14. A process for the preparation of a compound as claimed in claim 1 or claim 2 which comprises treating ( $\pm$ )-5-(3-chlorophenyl)- $\alpha$ -(4-chlorophenyl)- $\alpha$ -(1-methyl-1*H*-imidazol-5-yl)tetrazolo[1,5-*a*]quinazoline-7-methanamine or a pharmaceutically acceptable acid addition salt thereof to separate the constituent (+) and (-) enantiomers and isolating the (-) enantiomer or a pharmaceutically acceptable acid addition salt thereof.

## INTERNATIONAL SEARCH REPORT

Application No

EP 01/06747

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04 A61K31/519 A61P35/00 //(C07D487/04,257:00,  
239:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 21701 A (JANSSEN PHARMACEUTICA NV) 19 June 1997 (1997-06-19) cited in the application abstract	1,3
A	WO 98 49157 A (JANSSEN PHARMACEUTICA NV) 5 November 1998 (1998-11-05) cited in the application abstract	1,3
P,A	WO 00 39082 A (JANSSEN PHARMACEUTICA NV ) 6 July 2000 (2000-07-06) abstract	1,3

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

6 September 2001

Date of mailing of the international search report

14/09/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

## INTERNATIONAL SEARCH REPORT

for [REDACTED] patent family members

Inter [REDACTED] Application No

PCT/EP 01/06747

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9721701	A	19-06-1997	AU 711142 B	07-10-1999
			AU 7294896 A	03-07-1997
			BG 62615 B	31-03-2000
			BG 102458 A	30-06-1999
			BR 9610745 A	13-07-1999
			CN 1203598 A	30-12-1998
			CZ 9801573 A	14-10-1998
			EA 980443 A	29-10-1998
			EE 9800146 A	15-10-1998
			EP 0865440 A	23-09-1998
			HR 960576 A	28-02-1998
			HU 9900185 A	28-04-1999
			JP 10511405 T	04-11-1998
			KR 272676 B	15-11-2000
			NO 980927 A	08-06-1998
			NZ 320244 A	29-06-1999
			PL 325962 A	17-08-1998
			SK 70498 A	07-10-1998
			TR 9800825 T	21-08-1998
			US 6037350 A	14-03-2000
			US 6169096 B	02-01-2001
WO 9849157	A	05-11-1998	AU 7646098 A	24-11-1998
			BR 9809398 A	13-06-2000
			CN 1252800 T	10-05-2000
			EP 0977750 A	09-02-2000
			HU 0001122 A	28-04-2001
			NO 995169 A	27-12-1999
			PL 336468 A	19-06-2000
			SK 146199 A	12-06-2000
			TR 9902606 T	21-07-2000
			US 6177432 B	23-01-2001
WO 0039082	A	06-07-2000	AU 2795300 A	31-07-2000